Skip to main content
. Author manuscript; available in PMC: 2020 Dec 1.
Published in final edited form as: J Thorac Oncol. 2019 Aug 27;14(12):2152–2163. doi: 10.1016/j.jtho.2019.08.009

Figure 4.

Figure 4.

(A) RPP tumor bearing B6129F1 immunocompetent mice were treated with anti-PD-L1 (300μg, 1/7), LDG (40mg/kg, 1/7), SRA737 (100mg/kg, 2/7) and the combinations. Tumor growth curves are shown as mean tumor volume +/− SEM, ***p<0.001.

(B-G)SCLC tumors harvested at Day 21 and profiled by FACS analysis for CD3+CD45+CD8+ cytotoxic T-cells (B), PD1+TIM3+exhausted T-cells (C), CD86+ CD68+iNOS+ M1 macrophages (D), Arg1+CD68+M2 macrophages (E), F4/80- MHCII+ GR1-dendritic cells (F) and MDSCs (G). P-values were determined by ANOVA, ns, no significance; *, p < 0.05; **, p < 0.01; ***, p < 0.001.

(H) qPCR measurement of IFNβ, CXCL10 and CCL5 mRNA expression in RPP tumors resected from mice after 21 days of treatment as described in A. Data are presented as mean ± SD and p values were determined by t-test * p<0.05, **p<0.01, ***p<0.001.

HHS Vulnerability Disclosure